ASND

Conviction 80HealthcareScan · Thu, Jun 25, 2026

ASND$261.30+9.79%

ResistanceSupportVol 14Insider buyInsider sell

Vol MA14 789.62K

Mar 26Apr 14May 1May 19Jun 8Jun 25

Ascendis Pharma A/SBiotechnologywww.ascendispharma.com ↗

Price261.30

Change+9.79%

Gap+0.33%

Rel volume3.77×

Avg volume733.83K

Avg $ vol167.92M

SMA 20224.40

SMA 50231.49

SMA 200218.62

Price vs 50+12.88%

Price vs 200+19.53%

MA stackbullish

50/200 cross—

Supertrendup · 219.49

RSI (14)71

MACD hist4.25

MACD crossbull · 6d

Stoch %K / %D86 / 91

ADX (14)18

+DI / −DI35 / 15

RSI divergence—

MACD divergence—

ATR %+4.16%

ADR %4.52%

52w high261.30

52w low163.32

From 52w high+0.00%

Above 52w low+59.99%

New 52w highYes

SqueezeOff

Bollinger width22.70%

%B1.22

Donchian pos85.81%

Donchian high270.81

Donchian low203.80

AVWAP (52w high)256.55

vs AVWAP high+1.85%

AVWAP (52w low)216.99

vs AVWAP low+20.42%

OBV trendFlat

Chaikin MF (20)-0.12

Today vs 20d3.77×

Avg vol (14d)789.62K

Avg vol (20d)733.83K

Avg $ vol (20d)167.92M

Market cap16.19B

RS 3m (vs SPY)-1.83%

RS 6m (vs SPY)+11.28%

RS line new highNo

Trend template7/8

Technical rank86.7

1 week+13.04%

1 month+9.03%

3 months+18.29%

6 months+24.77%

1 year+45.90%

YTD+22.51%

P/E—

P/B—

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current—

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target—

Target upside—

Analyst rating—

Institutional100.94%

Ent. value16.19B

Revenue—

Net income—

Gross profit—

Free cash flow—

IndustryBiotechnology

ExchangeNasdaq

Shares out—

Employees1.19K

ListedMon, Apr 20, 2026

Free float46.55M

Float %75.1%

Short interest1.72M

Days to cover3.1d

Short volume66.0%

Squeeze score55 / 100

Next earningsThu, Aug 6, 2026 (42d)

EPS forecast$1.29 · 7 est

Last EPS vs est$0.32 vs $0.21

Last surprise+52.4% beat

Setup gradeA

Conviction80 / 100

Pattern quality—

Tech rank86.7 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance249.41

Support212.90

Days since event—

Candle confirm—

News sentiment—

Congress activity

Disclosed STOCK Act trades in ASND

All disclosures →

No recent disclosed trades by Congress in ASND. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ASND · 5 buys · 1 sell

Insider	Side	Shares	Value	Traded	Filed
SMITH SCOTT THOMAS EVP & Chief Financial Officer · Ordinary Shares · 2026-06-02	Buy	100	$22K	2026-06-02	2026-06-02
BIENAIME JEAN JACQUES Director · Ordinary Shares · 2026-05-29	Buy	100	$22K	2026-05-29	2026-06-01
BIENAIME JEAN JACQUES Director · Ordinary Shares · 2026-05-29	Buy	200	$44K	2026-05-29	2026-06-01
SMITH SCOTT THOMAS EVP & Chief Financial Officer · Ordinary Shares · 2026-05-29	Buy	250	$56K	2026-05-29	2026-06-01
BIENAIME JEAN JACQUES Director · Ordinary Shares · 2026-05-26	Buy	200	$48K	2026-05-26	2026-05-27
JENSEN FLEMMING STEEN See Remarks · Ordinary Shares · 2026-05-11	Sell	19.46K	$4.6M	2026-05-11	2026-05-12

SEC filings

EDGAR filings in ASND · 4 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.